$SHC

Petras Michael B. Jr. sold $5.4M of SHC

Petras Michael B. Jr. (Executive Chairman) sold 294,515 shares of Sotera Health Co (SHC) at $18.50 ($5.45M total) on 2026-08-17.

Original reporting
SEC EDGAR · Petras Michael B. Jr.
Published Aug 19, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SHC
Bearish
medium confidence
Mentioned
$SHC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SHCBearishLow
01

Why it matters

The insider sale reduces the insider's ownership, which may be interpreted by investors as a negative signal.

02

Market read

Primary insider sell news; modest impact on SHC stock.

03

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 6/10Novelty 5/10Timing: filing date 2026-08-19

Background

Form 4 filings disclose insider transactions; this is the first public report of this sale.

Company-level read

Ticker impact

$SHCBearishMedium confidence
Context

Executive Chairman Michael B. Petras Jr. sold 294,515 shares for $5.45 M, reducing his stake to 397,912 shares.

Expected impact

Short-term downward pressure; price may dip 1‑2% on news.

Evidence & confidence

Insider sales by a top officer are material, but the amount is modest relative to market cap; impact likely limited.

Market effects

Minimal; health‑care sector unlikely to be affected.

None

Low

Counterpoint

The sale could be unrelated to confidence; could be a planned liquidity event.

Key entities

  • Sotera Health Co

    Public health‑care services provider (ticker SHC).

  • Michael B. Petras Jr.

    Executive Chairman and director of Sotera Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BRKRMed

Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage

J.P. Morgan downgraded Bruker (BRKR) to Neutral and Sotera Health (SHC) to Underweight, citing uncertainty in their respective markets. Analyst Casey Woodring maintained a $70 price target for Bruker but expressed concerns about its exposure to lagging segments. For Sotera, Woodring lowered the price target to $17 from $18, citing underperformance tied to its medtech client base.

$AVTRMed

Q2 Earnings Highs And Lows: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks

Avantor (AVTR) reported Q2 revenue of $1.69B, flat YoY, beating estimates by 4.9%, with stock up 8.2%. Bruker (BRKR) reported $838.5M revenue, up 5.2% YoY, missing estimates by 1.9%, with stock down 11.6%. Sotera Health (SHC) reported $321.4M revenue, up 9.2% YoY, beating estimates by 3.8%, with stock up 2.9%. Bio-Techne (TECH) reported $321.2M revenue, up 1.3% YoY, beating estimates by 2%, with stock flat.